Neurocrine Biosciences, Inc.
NBIX
Clasificación en acciones
#1578
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Precio por acción
$135.96
Última sincronización: 2026-10-16
Capitalización bursátil
$13.82B
Cambio (1 día)
-0.72%
Cambio (1 año)
-2.95%
País
US
Comercio Neurocrine Biosciences, Inc. (NBIX)
Categoría
Healthcare
Margen Operativo de Neurocrine Biosciences, Inc. (NBIX)
Margen Operativo al October 2026 TTM: 23.38%
Según los informes financieros más recientes y el precio de las acciones de Neurocrine Biosciences, Inc., el margen operativo actual (TTM) es 23.38%. Al final de 2023, el margen operativo era 13.30%.
Historial de Margen Operativo de Neurocrine Biosciences, Inc. desde 2000 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 23.38% | -3.47% |
| 2024 | 24.22% | 82.11% |
| 2023 | 13.30% | -20.50% |
| 2022 | 16.73% | 85.07% |
| 2021 | 9.04% | -41.98% |
| 2020 | 15.58% | 69.90% |
| 2019 | 9.17% | 12.38% |
| 2018 | 8.16% | -110.04% |
| 2017 | -81.27% | -91.73% |
| 2016 | -982.48% | 106.18% |
| 2015 | -476.51% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -1,701.88% | -62,669.12% |
| 2012 | 2.72% | -93.79% |
| 2011 | 43.82% | -206.98% |
| 2010 | -40.96% | -97.75% |
| 2009 | -1,817.47% | -17.24% |
| 2008 | -2,196.18% | -87.33% |
| 2007 | -17,340.03% | 5,903.75% |
| 2006 | -288.82% | 1,326.98% |
| 2005 | -20.24% | -67.06% |
| 2004 | -61.44% | 45.35% |
| 2003 | -42.27% | -92.64% |
| 2002 | -574.20% | 439.66% |
| 2001 | -106.40% | -56.40% |
| 2000 | -244.04% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -98.35% |
US
|
|
| -149.01% | -106.37% |
US
|
|
| 25.57% | -98.91% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.77% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.